| |
Latest 10 SEC filings (by transaction date) for BOLD within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Series C Preferred Stock | C - Conversion | -2,464,286 | |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Series C Preferred Stock | C - Conversion | -13,964,285 | |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Series B Preferred Stock | C - Conversion | -3,000,000 | |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Series B Preferred Stock | C - Conversion | -17,000,000 | |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Common Stock | P - Open market or private purchase | 15,625 | $16.00 |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Common Stock | C - Conversion | 280,219 | |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Common Stock | P - Open market or private purchase | 296,875 | $16.00 |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Common Stock | C - Conversion | 1,587,912 | |
Apr 2/24 | Apr 2/24 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Direct Ownership | Series C Preferred Stock | C - Conversion | -7,142,857 | |
Apr 2/24 | Apr 2/24 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Direct Ownership | Series B Preferred Stock | C - Conversion | -3,703,704 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for BOLD within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Series C Preferred Stock | C - Conversion | -2,464,286 | |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Series C Preferred Stock | C - Conversion | -13,964,285 | |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Series B Preferred Stock | C - Conversion | -3,000,000 | |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Series B Preferred Stock | C - Conversion | -17,000,000 | |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Common Stock | P - Open market or private purchase | 15,625 | $16.00 |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Common Stock | C - Conversion | 280,219 | |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Common Stock | P - Open market or private purchase | 296,875 | $16.00 |
Apr 4/24 | Apr 2/24 | Ra Capital Management, L.P. | Indirect Ownership | Common Stock | C - Conversion | 1,587,912 | |
Apr 4/24 | Apr 2/24 | Burow Kristina | Indirect Ownership | Series B Convertible Preferred Stock | C - Conversion | -227,920 | |
Apr 4/24 | Apr 2/24 | Burow Kristina | Indirect Ownership | Series A Convertible Preferred Stock | C - Conversion | -454,212 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |
Madrigal Pharmaceuticals (OQ:MDGL) |